Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yosuke Minami

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
International Journal of Hematology|January 26, 2011
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisisKatsuya Sakai, Yuichi Ishikawa, Yumiko Mori, et al.
Internal Medicine (Tokyo, Japan)|August 18, 2015
Rhabdomyolysis Caused by Candida parapsilosis in a Patient with Acute Myeloid Leukemia after Bone Marrow TransplantationSeiji Kakiuchi, Kimikazu Yakushijin, Katsuya Yamamoto, et al.
Leukemia Research|March 25, 2026
Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling studyYuya Arai, Seiichiro Katagiri, SungGi Chi, et al.
Leukemia|April 17, 2023
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trialDelphine Réa, Carla Boquimpani, Michael J Mauro, et al.
Blood Advances|September 2, 2020
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphomaJoji Nagasaki, Yosuke Togashi, Takeaki Sugawara, et al.
European Journal of Haematology|December 17, 2009
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4Momoko Suzuki, Akihiro Abe, Shizuka Imagama, et al.
Clinical and Experimental Pharmacology & Physiology|June 23, 2016
Iron-chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formationMari Kono, Katsuyasu Saigo, Shiori Yamamoto, et al.
International Journal of Hematology|November 29, 2008
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapyAkihiro Abe, Yosuke Minami, Fumihiko Hayakawa, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 8, 2021
[Disseminated aspergillosis due to Aspergillus udagawae during immunosuppressive treatment for myelodysplastic syndrome]Ayumi Kuzume, Junichiro Yuda, Masahiro Abe, et al.
Biochimica Et Biophysica Acta|February 18, 2014
Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell linesYayoi Nishida, Naoki Mizutani, Minami Inoue, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
International Journal of Hematology|January 26, 2011
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisisKatsuya Sakai, Yuichi Ishikawa, Yumiko Mori, et al.
Internal Medicine (Tokyo, Japan)|August 18, 2015
Rhabdomyolysis Caused by Candida parapsilosis in a Patient with Acute Myeloid Leukemia after Bone Marrow TransplantationSeiji Kakiuchi, Kimikazu Yakushijin, Katsuya Yamamoto, et al.
Leukemia Research|March 25, 2026
Bi-directional association between RUNX1::RUNX1T1 and KIT mutations in acute myeloid leukemia: A multicenter genomic profiling studyYuya Arai, Seiichiro Katagiri, SungGi Chi, et al.
Leukemia|April 17, 2023
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trialDelphine Réa, Carla Boquimpani, Michael J Mauro, et al.
Blood Advances|September 2, 2020
The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphomaJoji Nagasaki, Yosuke Togashi, Takeaki Sugawara, et al.
European Journal of Haematology|December 17, 2009
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4Momoko Suzuki, Akihiro Abe, Shizuka Imagama, et al.
Clinical and Experimental Pharmacology & Physiology|June 23, 2016
Iron-chelating agent, deferasirox, inhibits neutrophil activation and extracellular trap formationMari Kono, Katsuyasu Saigo, Shiori Yamamoto, et al.
International Journal of Hematology|November 29, 2008
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapyAkihiro Abe, Yosuke Minami, Fumihiko Hayakawa, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 8, 2021
[Disseminated aspergillosis due to Aspergillus udagawae during immunosuppressive treatment for myelodysplastic syndrome]Ayumi Kuzume, Junichiro Yuda, Masahiro Abe, et al.
Biochimica Et Biophysica Acta|February 18, 2014
Phosphorylated Sp1 is the regulator of DNA-PKcs and DNA ligase IV transcription of daunorubicin-resistant leukemia cell linesYayoi Nishida, Naoki Mizutani, Minami Inoue, et al.
Pageof 11